Identification of [ 14C]fluasterone metabolites in urine and feces collected from dogs after subcutaneous and oral administration of [ 14C]fluasterone

Drug Metabolism and Disposition

Volumn 37, Issue 5, 2009, Pages 1089-1097

  Burgess, Jason P ^a   Green, Jonathan S ^a   Hill, Judith M ^a   Zhan, Qiao ^a   Lindeblad, Matthew ^c   Lyubimov, Alexander ^c   Kapetanovic, Izet M ^b   Schwartz, Arthur ^d   Thomas, Brian F ^a  

^a RTI INTERNATIONAL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4ALPHA HYDROXY 16ALPHA FLUORO 5 ANDROSTEN 17BETA OL; AGLYCONE; CARBON 14; DRUG METABOLITE; FLUASTERONE; GLUCURONIDE; UNCLASSIFIED DRUG; X ALPHA 4ALPHA DIHYDROXY 16ALPHA FLUORO 5 ANDROSTEN 17BETA OL; X BETA 4ALPHA DIHYDROXY 16ALPHA FLUORO 5 ANDROSTEN 17BETA OL; ANTINEOPLASTIC AGENT; BETA GLUCURONIDASE; DRUG DERIVATIVE; PRASTERONE; SULFATASE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG STRUCTURE; DRUG URINE LEVEL; ERYTHROCYTE; EXPERIMENTAL DOG; FECES ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID SCINTILLATION COUNTING; MALE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOACTIVITY; TANDEM MASS SPECTROMETRY; ANIMAL; BIOTRANSFORMATION; CHEMISTRY; DOG; FECES; MASS SPECTROMETRY; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; URINE;

CANIS FAMILIARIS;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEHYDROEPIANDROSTERONE; DOGS; ERYTHROCYTES; FECES; GLUCURONIDASE; GLUCURONIDES; INJECTIONS, SUBCUTANEOUS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; SULFATASES;

EID: 66449136916     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.023614     Document Type: Article

References (19)

1. Allolio B and Arlt W (2002) DHEA treatment: myth or reality? Trends Endocrinol Metab 13:288-294.
2. Burgess JP, Wintermute JS, Thomas BF, and Kapetanovic IM (2006) Complete 1H and 13C assignments of fluorinated analogs of dehydroepiandrosterone. Magn Reson Chem 44:1051-1053.
3. Dorgan JF, Reichman ME, Judd JT, Brown C, Longcope C, Schatzkin A, Forman M, Campbell WS, Franz C, Kahle L, et al. (1996) Relation of energy, fat, and fiber intakes to plasma concentrations of estrogens and androgens in premenopausal women. Am J Clin Nutr 64:25-31.
4. Dorgan JF, Stanczyk FZ, Longcope C, Stephenson HE Jr, Chang L, Miller R, Franz C, Falk RT, and Kahle L (1997) Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5-androstene-3 beta, 17 beta-diol to risk of breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 6:177-181.
5. Ebeling P and Koivisto VA (1994) Physiological importance of dehydroepiandrosterone. Lancet 343:1479 -1481.
6. Frye RF, Kroboth PD, Kroboth FJ, Stone RA, Folan M, Salek FS, Pollock BG, Linares AM, and Hakala C (2000) Sex differences in the pharmacokinetics of dehydroepiandrosterone (DHEA) after single- and multiple-dose administration in healthy older adults. J Clin Pharmacol 40:596-605.
7. Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, Barbieri RL, and Speizer FE (1998) Plasma sex steroid hormone levels and risk of breast cancer in postmeno- pausal women. J Natl Cancer Inst 90:1292-1299.
8. Li S, Yan X, Belanger A, and Labrie F (1994) Prevention by dehydroepiandrosterone of the development of mammary carcinoma induced by 7,12-dimethylbenz(a)anthracene (DMBA) in the rat. Breast Cancer Res Treat 29:203-217.
9. McCormick DL, Johnson WD, Kozub NM, Rao KV, Lubet RA, Steele VE, and Bosland MC (2007) Chemoprevention of rat prostate carcinogenesis by dietary 16alpha-fluoro-5-androsten- 17-one (fluasterone), a minimally androgenic analog of dehydroepiandrosterone. Carcinogenesis 28:398-403.
10. McCormick DL, Rao KV, Johnson WD, Bowman-Gram TA, Steele VE, Lubet RA, and Kellof GJ (1996) Exceptional chemopreventive activity of low-dose dehydroepiandrosterone in the rat mammary gland. Cancer Res 56:1724-1726.
11. Moore MA, Thamavit W, Tsuda H, Sato K, Ichihara A, and Ito N (1986) Modifying influence of dehydroepiandrosterone on the development of dihydroxy-di-n-propylnitrosamine-initiated lesions in the thyroid, lung and liver of F344 rats. Carcinogenesis 7:311-316.
12. Nyce JW, Magee PN, Hard GC, and Schwartz AG (1984) Inhibition of 1,2-dimethylhydrazine- induced colon tumorigenesis in BALB/c mice by dehydroepiandrosterone. Carcinogenesis 5:57-62.
13. Osawa E, Nakajima A, Yoshida S, Omura M, Nagase H, Ueno N, Wada K, Matsuhashi N, Ochiai M, Nakagama H, et al. (2002) Chemoprevention of precursors to colon cancer by dehydro- epiandrosterone (DHEA). Life Sci 70:2623-2630.
14. Pashko LL, Rovito RJ, Williams JR, Sobel EL, and Schwartz AG (1984) Dehydroepiandros- terone (DHEA) and 3beta-methylandrost-5-en-17-one: inhibitors of 7,12-dimethylbenz[a]an- thracene (DMBA)-initiated and 12-O- tetradecanoylphorbol-13-acetate (TPA)-promoted skin papilloma formation in mice. Carcinogenesis 5:463-466.
15. Perkins SN, Hursting SD, Haines DC, James SJ, Miller BJ, and Phang JM (1997) Chemopre- vention of spontaneous tumorigenesis in nullizygous p53-deficient mice by dehydroepiandro- sterone and its analog 16alpha-fluoro-5-androsten-17-one. Carcinogenesis 18:989 -994.
16. Rainey WE, Carr BR, Sasano H, Suzuki T, and Mason JI (2002) Dissecting human adrenal androgen production. Trends Endocrinol Metab 13:234-239.
17. Schwartz AG (1979) Inhibition of spontaneous breast cancer formation in female C3H (Avy/a) mice by long-term treatment with dehydroepiandrosterone. Cancer Res 39:1129-1132.
18. Schwartz AG and Pashko LL (1995) Cancer prevention with dehydroepiandrosterone and nonandrogenic structural analogs. J Cell Biochem Suppl 22:210-217.
19. Schwartz AG and Tannen RH (1981) Inhibition of 7,12-dimethylbenz[a] anthracene- and urethan- induced lung tumor formation in A/J mice by long-term treatment with dehydroepiandros- terone. Carcinogenesis 2:1335-1337.